Related to AstraZeneca, Agendia, and The Netherlands Cancer Institute Team Up to Develop Colorectal Cancer Therapies

• First Phase III Study with Targacept and AstraZeneca’s Adjunctive Antidepressant Misses Primary Endpoint
  
• Neoprobe Licenses AstraZeneca’s Alzheimer Plaque Imaging Agent
  
• AstraZeneca, Targacept’s TC-5214 Fails as Adjunct to Antidepressants
  
• Hutchinson, AstraZeneca Ink Deal for c-Met Inhibitor with $20M Up Front
  
• Agendia to Leverage Rubicon’s RNA Amplification Technology in Breast Cancer Diagnostics
  
• Targacept, AstraZeneca Ditch Depression Drug After All Four Phase III Studies Fail
  
• AstraZeneca Forges Pact Around Five Amgen Clinical-Stage Anti-Inflammatory mAbs
  
• NMR Structural Biology Firm Signs First Drug Discovery Collaboration with AstraZeneca
  
• Agendia to Launch Colon Cancer Prognostic Test
  
• AstraZeneca, Rigel Sign Potentially $100M Asthma Drug Deal
  
• FDA Approves Qiagen’s KRAS Companion Diagnostic And New Use for Erbitux
  
• Targacept and AZ Restructure Partnership as Success Proves Elusive
  
• Horizon, AstraZeneca Seek Kinase-Targeting Cancer Drugs
  
• AstraZeneca, BIND Enter $200M+ Cancer Nanomedicine Agreement
  
• Pharma Touting Phase II/III Wins in Run-Up to ASCO
  
• Isis Wins $10M After AstraZeneca Adds Prostate Cancer Drug to Collaboration
  
• DxS to Provide a Companion Diagnostic for AstraZeneca’s NSCLC Drug
  
• Agendia Receives FDA Approval for MammaPrint Assay that Broadens Its Lab Capacity
  
• Agendia, MD Anderson, and The Netherlands Cancer Institute Ally to Improve Colon Cancer Prognosis
  
• Life Technologies, Oxford BRC, AstraZeneca, and ORD Ally on Cancer Diagnostic Project